Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79.74 | 61.67 | 82.68 | 80.82 | 70.17 | 63.66 | 71.20 | 75.65 | 78.87 | 63.43 | 71.77 | 79.76 |
| Expenses | 79.51 | 61.56 | 81.32 | 78.24 | 66.80 | 59.48 | 71.07 | 75.52 | 79.23 | 64.08 | 73.01 | 78.87 |
| Operating Profit | 0.23 | 0.11 | 1.36 | 2.58 | 3.37 | 4.18 | 0.13 | 0.13 | -0.36 | -0.65 | -1.24 | 0.89 |
| OPM % | 0.29% | 0.18% | 1.64% | 3.19% | 4.80% | 6.57% | 0.18% | 0.17% | -0.46% | -1.02% | -1.73% | 1.12% |
| Other Income | 0.30 | 0.42 | 0.30 | 0.59 | 0.49 | 0.00 | -0.11 | 0.69 | 0.05 | 0.40 | -0.31 | 0.99 |
| Interest | 0.13 | 0.23 | 0.11 | 0.19 | 0.17 | 0.10 | 0.22 | 0.44 | 0.26 | 0.13 | 0.14 | 0.11 |
| Depreciation | 0.16 | 0.16 | 0.16 | 0.16 | 0.17 | 0.17 | 0.16 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 0.24 | 0.14 | 1.39 | 2.82 | 3.52 | 3.91 | -0.36 | 0.21 | -0.75 | -0.57 | -1.88 | 1.58 |
| Tax % | 175.00% | -142.86% | 0.00% | 26.60% | 24.43% | 28.90% | 11.11% | 209.52% | -21.33% | -19.30% | 8.51% | 44.94% |
| Net Profit | -0.19 | 0.34 | 1.40 | 2.07 | 2.66 | 2.78 | -0.40 | -0.23 | -0.59 | -0.46 | -2.04 | 0.88 |
| EPS in Rs | -0.61 | 1.10 | 4.53 | 6.70 | 8.61 | 9.00 | -1.29 | -0.74 | -1.91 | -1.49 | -6.60 | 2.85 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | 290 | 294 |
| Expenses | 62 | 69 | 87 | 108 | 131 | 170 | 197 | 287 | 279 | 276 | 292 | 295 |
| Operating Profit | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 2 | 10 | -2 | -1 |
| OPM % | 1.9% | 5% | 6% | 2.9% | 4.8% | 4.8% | 11% | 8% | 0.9% | 3.6% | -0.7% | -0.5% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 3 | 10 | -3 | -2 |
| Tax % | 33% | 37% | 35% | 29% | 27% | 27% | 27% | 26% | 14% | 28% | 11% | |
| Net Profit | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 | 7 | -3 | -2 |
| EPS in Rs | 0.97 | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 | 6.99 | 23.01 | -10.71 | -7.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 2% | 2% | 14% | 4% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 16% | 10% | -2% | 5% | ||
| Compounded Profit Growth | % | % | % | -146% | ||
| Stock Price CAGR | 19% | 3% | -17% | -22% | ||
| Return on Equity | 14% | 13% | 2% | -5% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 | 69 | 65 |
| Borrowings | 3 | 6 | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 8 | 10 | 11 |
| Other Liabilities | 10 | 17 | 14 | 13 | 14 | 25 | 19 | 30 | 35 | 48 | 40 | 46 |
| Total Liabilities | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |
| Fixed Assets | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | 10 | 12 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 4 |
| Other Assets | 19 | 27 | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 108 | 107 | 108 |
| Total Assets | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -1 | -0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 | -10 | 9 |
| Cash from Investing Activity | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | -0 | 0 | -3 |
| Cash from Financing Activity | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 | 0 | -0 |
| Net Cash Flow | -0 | -0 | -1 | -1 | 1 | -1 | -0 | 14 | -3 | -2 | -10 | 6 |
| Free Cash Flow | -1 | -1 | -4 | -0 | 2 | -3 | 3 | 16 | -11 | 9 | -11 | 6 |
| CFO/OP | -29% | -25% | -73% | 17% | 126% | -7% | 81% | 78% | 0% | 503% | -84% | -493% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 93 | 59 | 86 | 69 | 74 | 67 | 72 | 61 | 90 | 72 | 64 |
| Inventory Days | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 | 52 | 56 |
| Days Payable | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 65 | 53 | 55 |
| Cash Conversion Cycle | 36 | 26 | 58 | 70 | 52 | 61 | 53 | 51 | 62 | 53 | 71 | 65 |
| Working Capital Days | 19 | 14 | 34 | 32 | 37 | 39 | 36 | 32 | 40 | 47 | 68 | 52 |
| ROCE % | 7% | 5% | 16% | 23% | 12% | 22% | 24% | 52% | 35% | 3% | 13% | -3% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 48.64% | 48.64% | 48.64% | 48.64% | 48.95% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% |
| FIIs | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 0.00% | 3.24% | 3.24% | 3.24% | 3.24% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 48.13% | 48.13% | 48.13% | 48.13% | 47.81% | 47.66% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.66% |
| No. of Shareholders | 8,445 | 8,065 | 7,478 | 7,169 | 6,984 | 6,844 | 6,785 | 6,752 | 6,699 | 6,488 | 6,311 | 6,330 |
Fundamentals
Market Cap₹ 74.1 Cr.
Current Price₹ 240
Book Value₹ 221
ROCE-2.88 %
ROE-5.19 %
Dividend Yield0.41 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)5%
Compounded Profit Growth (TTM)-146%
Standalone figures.
Valuation
Market capRs 72 Cr
Enterprise valueRs 77 Cr
Price to book1.06x
Price to sales0.24x
EV / sales0.26x
Price to cash flow8.10x
Earnings yield-3.07%
P/E, 3-year average30.64x
P/B, 3-year average1.27x
P/E, 5-year average19.23x
P/B, 5-year average1.77x
Profitability
Operating margin (excl. other income)-0.73%
Operating margin (incl. other income)-0.45%
EBITDA margin-0.08%
Pre-tax margin-0.55%
Net profit margin-0.75%
Net margin, latest quarter1.10%
ROE-4.73%
ROCE-2.52%
ROA-2.69%
ROE, 3-year average3.01%
ROCE, 3-year average5.08%
ROA, 3-year average1.66%
ROE, 5-year average16.84%
ROCE, 5-year average20.50%
ROA, 5-year average9.14%
ROIC (approx.)-1.49%
Tax rate-11.07%
Other income / net worth1.19%
Growth
Sales growth (latest year)1.35%
Profit growth (latest year)-146.55%
Sales CAGR, 3 years-2.30%
Sales CAGR, 5 years10.11%
Sales growth QoQ11.13%
Sales growth YoY (latest quarter)5.43%
Per share
EPS (TTM)Rs -7.15
EPS (latest year)Rs -10.71
EPS (latest quarter)Rs 2.85
EPS, 3-year averageRs 6.43
EPS, 5-year averageRs 25.74
Book value per shareRs 220.67
Sales per shareRs 951.00
Cash flow per shareRs 28.74
Free cash flow per shareRs 19.42
Dividend per share, 3-year averageRs 1.00
Dividend per share, 5-year averageRs 1.00
Dividends
Dividend payout, 3-year average9.36%
Dividend payout, 5-year average5.60%
Efficiency
Asset turnover2.33x
Fixed asset turnover24.74x
Inventory turnover6.58x
Inventory days55 days
Debtor days64 days
Debtors turnover5.68x
Creditor days55 days
Cash conversion cycle65 days
Working capital days52 days
Leverage
Total debtRs 11 Cr
Cash and bankRs 6 Cr
Net debtRs 5 Cr
Debt to equity0.16x
Interest coverage-1.53x
Owners' fund to total sources54.80%
Debt to assets8.61%
Cash flow
Cash from Operating Activity (latest year)Rs 9 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 6 Cr
Free cash flow (latest year)Rs 6 Cr
FCFE (approx.: FCF + change in debt)Rs 7 Cr
Cash from ops / profit, 5 years0.40x
Sales to cash flow32.63x
Statement figures
Net sales (TTM)Rs 294 Cr
Net sales (latest year)Rs 290 Cr
Sales (latest quarter)Rs 80 Cr
Operating profit excl. other income (latest year)Rs -2 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -1 Cr
Profit before tax (TTM)Rs -2 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs -3 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 287 Cr
Total expenditure (latest year)Rs 292 Cr
Total income (latest year)Rs 291 Cr
Share capitalRs 3 Cr
ReservesRs 65 Cr
Shareholders' fundsRs 68 Cr
Total assetsRs 124 Cr
Net blockRs 12 Cr
Capital work in progressRs 1 Cr
InvestmentsRs 4 Cr
ReceivablesRs 51 Cr
InventoryRs 44 Cr
Other liabilitiesRs 46 Cr
Shares outstanding (crore)0.31
Ownership
Promoter holding49.09% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 1.06 is at the 13th percentile (median 1.66).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530125 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +4.4% | -2.8% | +7.2 pts |
| 1 month | -5.2% | -6.8% | +1.6 pts |
| 3 months | +6.0% | -7.6% | +13.6 pts |
| 3 years | -41.8% | +14.2% | -56.0 pts |
| 5 years | +15.0% | +27.9% | -12.8 pts |
Red flags
F-score 3 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹80 Cr +5.4% vs Jun 2025.
Net profit ₹1 Cr +482.6%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd (530125) has a market capitalisation of Rs 74.1 Cr. at the 2026-10-01 close.
What were Samrat Pharmachem Ltd's latest quarterly results?
In the Jun 2026 quarter, Samrat Pharmachem Ltd sales was Rs 80 Cr (+5.4% vs Jun 2025) and net profit was Rs 1 Cr.